BioCentury This Week cover image

Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

BioCentury This Week

00:00

Nectar

There are a lot of new structures of the io too, molecule companies are developing. The whole idea with these next generation i l tos is that you wanted to design them to avoid binding the i to receptor alpa chain but to bind the rest of the receptor bcause that would prevent you from sort of activating the suppressive immune cells and the efector immune cells. There's a pretty big line of these not alpa iltos that our colleag daniel, looked into. And there are some very cool rapics in her story,. But she looked into the pipe line beyond that star and grouped them by the different types of structure. So nectar avoided binding i to

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app